Advertisement
Correction

Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer

Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen and Carey K. Anders
DOI: 10.1158/1078-0432.CCR-21-0193 Published March 2021

In the original version of this article (1), the values stated for fub,abemaciclib, fub,M2, and fub,M20 in the legend for Fig. 3 were incorrect. These values have been corrected in the latest online HTML and PDF versions of this article. The authors regret these errors.

Footnotes

  • Clin Cancer Res 2021;27:1582

Reference

  1. 1.↵
    1. Tolaney SM,
    2. Sahebjam S,
    3. Le Ruhn E,
    4. Bachelot T,
    5. Kabos P,
    6. Awada A,
    7. et al.
    A phase II study of abemaciclib in patients with brain metastases secondary to hormone receptor-positive breast cancer. Clin Cancer Res 2020;26:5310–9.
    OpenUrlAbstract/FREE Full Text
Back to top
View this article with LENS

Open full page PDF
Article Alerts
Email Article
Citation Tools
Correction: A Phase II Study of Abemaciclib in Patients with Brain Metastases Secondary to Hormone Receptor–positive Breast Cancer
Sara M. Tolaney, Solmaz Sahebjam, Emilie Le Rhun, Thomas Bachelot, Peter Kabos, Ahmad Awada, Denise Yardley, Arlene Chan, Pierfranco Conte, Véronique Diéras, Nancy U. Lin, Melissa Bear, Sonya C. Chapman, Zhengyu Yang, Yanyun Chen and Carey K. Anders
Clin Cancer Res March 1 2021 (27) (5) 1582; DOI: 10.1158/1078-0432.CCR-21-0193
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section

Advertisement